My Papers
0
Cost-effectiveness analysis model for sotagliflozin compared with insulin monotherapy for patients with type 1 diabetes and chronic kidney disease
0

That is the title of my latest paper in JMCP with co-authors Jaehong Kim, Shanshan Wang, Moises Marin, Slaven Sikirica, and Mariam Anderson. The study ...

0
Why CMS/AHIP’s prior authorization changes won’t hurt payers. – Healthcare Economist
0

Myself and Kristy Piccinini, PhD from FTI Consulting published a new commentary in The Evidence Base titled ...

0
Two approaches for measuring treatment value under uncertainty – Healthcare Economist
0

That is the title of my new paper in the Forum for Health Economics and Policy (FHEP) and the subtitle is “Estimating Insurance Value and Risk ...

Som2ny Network
Logo
Compare items
  • Total (0)
Compare
0